Telix Pharmaceuticals (ASX:TLX) said the first patient has been administered its drug candidate TLX300-CDx in the Phase 1 ZOLAR1 trial for advanced metastatic soft tissue sarcoma (STS), according to a Tuesday statement by the company.
The trial aims to assess the drug's biodistribution, safety, and optimal dose using positron emission tomography (PET), the statement said.
TLX300-CDx targets PDGFRα, a protein often over-expressed in STS, the statement added.
The study will inform future therapeutic approaches for treating the disease, the company said.
Telix holds the rights to develop and commercialize the radiolabelled drug, the company added.
Shares of the company fell 3% on market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。